AeroRx Therapeutics Presents Positive Phase 2a Data for Inhaled AERO-007, the First Potential Nebulized LABA+LAMA Fixed-Dose Combination in Development for COPD
AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the presentation of positive Phase 2a data for inhaled AERO-007, the first potential nebulized LABA+LAMA fixed-dose combination in clinical development for chronic obstructive pulmonary disease (COPD). The data were presented at the American Thoracic Society (ATS) 2026 International Conference. The data support AERO-007’s continued development as a potential first-line maintenance dual bronchodilation therapy for COPD patients who require or prefer nebulized treatment, with both dose levels demonstrating robust and sustained improvements in lung function and a favorable tolerability profile.
AeroRx Therapeutics Announces $21 Million Series A Financing to Advance Inhaled AERO-007, the First Nebulized LABA/LAMA for COPD, into Late-Stage Clinical Development
AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced the closing of a $21 million Series A financing led by Avalon BioVentures, with participation from Correlation Ventures, Alexandria Venture Investments, and others. Proceeds will support late-stage clinical development of AeroRx’s lead candidate, inhaled AERO-007, the first nebulized LABA/LAMA combination in development as a potential first-line maintenance therapy for chronic obstructive pulmonary disease (COPD).
AeroRx Therapeutics Announces Topline Positive Phase 2a Data for Inhaled AERO-007, the First Nebulized LABA/LAMA Combination in Development for COPD
AeroRx Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary nebulized combination therapies for chronic respiratory diseases, today announced positive Phase 2a proof-of-concept results for its lead candidate inhaled AERO-007, which is in development as a first-line maintenance therapy combining a long-acting beta2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). Topline data showed that AERO-007 was well tolerated with rapid-onset and sustained 24-hour bronchodilation at both low and high doses. AeroRx plans to present the full dataset at an upcoming scientific conference.
